Articles tagged with Multiple Sclerosis
A team from the University of Utah has received a $275,000 NIH grant to study brain tissue from patients with primary progressive multiple sclerosis (PPMS) using advanced technology called deep sequencing. The goal is to identify viruses that might play a role in the development of PPMS and potentially lead to new treatments.
A new oral drug, teriflunomide, has been shown to significantly reduce the relapse rate of people with multiple sclerosis and slow the progression of the disease. The drug was found to be effective in increasing the time between relapses and reducing disease progression by almost 30%.
A systematic review found that taking natalizumab for two years lowers the number of MS patients who experience relapses and progression of disability. The medication also delays disease progression, according to MRI brain scans.
A meta-analysis found a strong association between CCSVI and multiple sclerosis, but the low quality of included studies prevents a definitive conclusion. The variation in study results suggests that factors such as sample size, ultrasound techniques, and training of operators may contribute to the heterogeneity.
A review of eight studies found an association between chronic cerebrospinal venous insufficiency and multiple sclerosis, but poor study quality and inconsistencies hinder definitive conclusions. Further research is needed to clarify the relationship.
A glucosamine-like dietary supplement, N-acetylglucosamine (GlcNAc), suppresses multiple sclerosis attacks by inhibiting abnormal T-cell growth and function. The study, published in The Journal of Biological Chemistry, suggests a novel mechanism for affecting T-cell function and autoimmunity.
Researchers at University of California - San Diego have discovered that inhibiting a single enzyme helps slow disease progression in a mouse model of multiple sclerosis. The study suggests that targeting fatty acid metabolism could lead to new therapies with fewer side effects.
Researchers at Cleveland institutions collaborate on a ground-breaking study testing the feasibility and safety of using mesenchymal stem cells to treat multiple sclerosis. The Phase 1 trial aims to decrease disease activity and promote repair in patients with MS.
Researchers identified 29 new genetic variants linked to multiple sclerosis, shedding light on immunological pathways and immune system involvement. The study confirms 23 known genetic associations and provides insight into a possible link between genetic and environmental risk factors.
An international team of scientists identified 29 new genetic variants linked to multiple sclerosis, providing key insights into the biology of the disease. The study confirms 23 previously known genetic associations and doubles the number of genes associated with MS.
A large international study has identified 29 new genetic variants associated with multiple sclerosis, providing key insights into the biology of the disease. The research highlights the pivotal role of the immune system in causing damage and helps explain the nature of the immune attack on the brain and spinal cord.
A recent study by Yale University researchers has identified more than two dozen new genetic variants linked to disease risk in multiple sclerosis and other autoimmune diseases. The findings suggest a common genetic basis for many devastating immune system disorders.
A new study examines the cost-effectiveness of MS drugs in the US, finding that they come at a high cost compared to basic therapy and other chronic diseases. The research suggests that reducing medication prices by 67% could improve the cost-benefit ratio and support earlier disease-modifying therapy.
A study analyzed data from 844 individuals with early-stage Multiple Sclerosis and found that disease-modifying drugs provide modest health gains, but their cost is more than 8 times higher than considered reasonable. The study's authors highlight the need to reevaluate treatment costs to control healthcare expenses.
People with multiple sclerosis are at risk of poor bone health in the early stages of the disease, with 51% experiencing osteoporosis or osteopenia. Low vitamin D levels can lead to reduced calcium absorption and bone mineralization.
New research from the American Academy of Neurology found that breastfeeding does not have a protective effect on multiple sclerosis relapses. In fact, women with high disease activity and high risk of postpartum relapses may need to resume MS treatment after giving birth.
A team of researchers has discovered a naturally occurring disease in monkeys that shares similarities with multiple sclerosis, providing new insights into the cause of the disease. The discovery is associated with a herpes virus and could lead to significant advancements in MS research and treatment.
Researchers analyzed data from BC MS Clinics' database and BC Perinatal Database Registry to compare pregnancy outcomes in women with MS to those without the disease. Babies born to mothers with MS did not have significantly different gestational age or birth weight, but mothers with greater disability had slightly elevated risk of adv...
A Rush University Medical Center scientist is studying cinnamon's effects on multiple sclerosis, a disease that attacks the central nervous system. The research aims to understand how cinnamon's anti-inflammatory property may counteract the disease process in mice.
Scientists at The University of Nottingham have discovered a synthetic chemical compound that reduces MS severity by inhibiting pro-inflammatory signals while stimulating interferon-beta production. The findings highlight a potential new mechanism for treating the chronic inflammatory disease, which affects over 100,000 people in the UK.
A multidisciplinary panel recommends careful, well-designed research on chronic cerebrospinal venous insufficiency (CCSVI) in multiple sclerosis patients. The goal is to evaluate the role of vein widening with angioplasty and potential stent placement in improving symptoms.
A study at The University of Nottingham found that group therapy sessions can reduce anxiety and depression in MS patients, improving their quality of life. The treatment reduced costs for the NHS by almost £470 per patient, with savings also seen in GP visits and outpatient hospital costs.
Researchers have found that shingles may be associated with an increased risk of developing multiple sclerosis, particularly in the year following a shingles attack. The study suggests that this risk is still relatively low and varies by geographical location and income.
Researchers at UCI have identified a unifying mechanism responsible for multiple sclerosis, suggesting personalized therapies based on genetic factors. Vitamin D3 and GlcNAc supplements can reverse the effects of four human MS genetic factors, restoring normal protein modification and potentially treating the disease.
A recent study published in Neurology found that stress does not increase the risk of developing multiple sclerosis. Researchers studied two groups of nurses and found no significant link between severe stress at home or during childhood and adolescence and the development of MS.
African Americans with multiple sclerosis have lower vitamin D levels than those without the disease. The study suggests low vitamin D may be a risk factor for developing multiple sclerosis, but other factors such as genes and environmental triggers also play a role in disease severity.
Researchers at UC Santa Barbara developed a new method of nanoscopic imaging that could lead to early detection and diagnosis of multiple sclerosis. The study focused on the myelin sheath, a membrane surrounding nerves compromised in MS patients.
Vitamin D deficiency is prevalent among African-American patients with MS, largely due to regional UV exposure and geographic factors. Low vitamin D levels were found in nearly 77% of MS patients compared to 71% without the disease.
Researchers discovered that Viagra reduces multiple sclerosis symptoms by reducing inflammation and facilitating myelin repair. A daily treatment resulted in a 50% practically complete recovery rate in animal models with the disease.
Researchers at University of Granada analyzed antibody levels in patients with multiple sclerosis and found a statistically significant association between viral infection markers and the condition. Further research is needed to confirm the link.
Researchers discovered that estrogen receptors in the brain help turn off genes leading to chronic inflammation. This finding may lead to new treatments for multiple sclerosis and other neurodegenerative conditions.
Researchers have created a new X-ray method called SAXS-CT to map the myelin sheaths of nerve cells in detail. This can provide insights into neurodegenerative diseases such as cerebral malaria, multiple sclerosis, and Alzheimer's disease.
A paper in Nature notes the power of social media in shaping research priorities in Canada, particularly in the case of a controversial multiple sclerosis treatment. Researchers call for more effective communication tools between scientists and the public to ensure patients' concerns are heard.
Researchers have identified GM-CSF as a driving force behind autoimmune diseases like MS. Blocking its activity may lead to new treatments for the disease. Dr. Abdolmohamad Rostami and his team found that GM-CSF is responsible for disease manifestation in an experimental animal model.
Researchers found GM-CSF crucial for MS disease progression, neutralizing it could reverse inflammation. A clinical trial is set to launch this year to test GM-CSF neutralization in patients.
Researchers found a strong association between low sunlight exposure and an increased risk of developing multiple sclerosis (MS) in people who have had infectious mononucleosis. The study, published in the April 2011 issue of Neurology, suggests that vitamin D deficiency may play a role in this association.
A newly developed compound, SR1001, has been shown to effectively suppress the severity of multiple sclerosis in animal models with minimal side effects. The discovery holds promise for treating other autoimmune diseases and targets a specific cell type involved in autoimmunity.
Researchers found that a subgroup of PPMS patients can convert to PRMS, with faster disease progression and increased risk for sustained disability. The study emphasizes the need for clinicians to consider evaluating this subgroup differently in assessing prognosis and clinical course.
A recent study found that chronic cerebral venous insufficiency (CCSVI) is more prevalent in multiple sclerosis (MS) patients, particularly those with progressive forms of the disease. The research suggests CCSVI may be a consequence of MS progression rather than a cause, warranting further investigation.
Researchers at Mayo Clinic have created a tool that uses cerebrospinal fluid test results to predict disability timelines for patients with progressive multiple sclerosis. The study found that patients with higher levels of certain proteins in their CSF are more likely to experience a faster onset of disability.
A Phase III clinical study found that laquinimod reduced annual relapse rates by 23% and disability progression by 36%. Laquinimod also slowed brain atrophy by 33%. The study involved 1,106 people with relapsing-remitting MS in 24 countries.
Researchers have shown that angioplasty to widen internal jugular and azygos veins is safe for multiple sclerosis patients. The treatment improved blood flow and reduced symptoms in 97% of patients with no significant complications.
Researchers found that people who used marijuana performed significantly worse in attention, speed of thinking, executive function, and visual perception, with some scoring approximately one third lower than non-users. The study suggests that prolonged marijuana use may add to the cognitive burden already experienced by MS patients.
Scientists have discovered a previously unknown type of axonal degeneration called focal axonal degeneration (FAD), which is responsible for damage to nerve cells in multiple sclerosis. FAD can be reversed if recognized and treated early, suggesting a potential target for therapeutic intervention.
A long-term study reports the effectiveness of stem cell transplants in replacing bone marrow and reducing disease activity in people with rapidly progressive MS. The treatment showed promising results, with an average improvement in symptoms lasting two years.
A study published in Neurology has found that children with a specific gene variation are at higher risk of developing Multiple Sclerosis. The research identifies the HLA-DRB1 allele as a key factor in pediatric-onset MS, which can provide insights into disease causes and potentially lead to earlier diagnoses and new therapies.
The revised McDonald Criteria simplify the diagnostic process by incorporating new data on MRI, speeding up diagnosis while maintaining accuracy. The updated criteria apply primarily to individuals with clinically isolated syndrome or symptoms consistent with a central nervous system inflammatory demyelinating disease.
Researchers found a delay in detecting CADASIL, a vascular brain disorder, and diagnosed it as multiple sclerosis in some patients. The study suggests that CADASIL often goes misdiagnosed due to similarities with MS in brain MRIs and symptoms.
Researchers from Washington University School of Medicine successfully blocked harmful immune cells from entering the brain in mice with a condition similar to multiple sclerosis. The breakthrough discovery, made using an anti-cancer drug, prevents symptoms and provides early evidence for a potential new treatment.
Researchers at Ruhr-University Bochum have found that fumaric acid salts exhibit neuroprotective effects in Multiple Sclerosis by detoxifying radicals and supporting nerve cell survival. This discovery offers new hope for treating MS, potentially combining with existing medications.
New research suggests that increasing vitamin D3 supplies through sunlight exposure may be a safe and effective therapy for Multiple Sclerosis (MS). Studies found that patients with the highest vitamin D3 supplies experienced fewer attacks and slower disease progression.
Researchers at Wayne State University found that targeting white blood cells known as T cells is effective in blocking the disease in an animal model of MS. This study resolves a long-disputed issue and provides a valid therapeutic approach for the most common form of multiple sclerosis.
Research found that individuals with MS performed better on learning and memory tests during cooler days compared to warmer days. The study suggests a link between warm weather and cognitive impairment in people with MS, which could inform life decisions and clinical treatment.
Damage to a specific area of the brain and decreased noradrenaline levels are linked to multiple sclerosis progression. The study found that noradrenaline plays a crucial role in preventing inflammation and preserving blood-brain barrier integrity.
A study published in Neurology found that people with higher sun exposure and vitamin D levels were less likely to develop multiple sclerosis. The researchers also discovered that increased UV light exposure and skin damage from sun exposure reduced the risk of developing the disease.
New research suggests histamine plays a critical role in preventing or lessening the effects of multiple sclerosis. Histamine reduces MS-causing T cell proliferation and interferon-gamma production, and its ability to adhere to brain vessels.
The American Academy of Neurology recommends using plasma exchange to treat people with severe relapses in multiple sclerosis (MS) and related diseases, as well as those with certain kinds of nerve disorders known as neuropathies. Plasma exchange has been found effective for treating severe flares in relapsing forms of MS.
Researchers have discovered a new factor in multiple sclerosis (MS) that can serve as a potential target for therapeutics. The study found that inhibiting the molecular switch EMMPRIN reduces MS-like symptoms in mice.
A study of over 2,100 individuals with multiple sclerosis found that women were 1.4 times more likely to carry the HLA gene variant associated with MS than men. The researchers also discovered that women with this gene variant were more likely to pass it on to other women in their families.
A new study published in the Journal of Lipid Research found that oxysterols, previously thought to be associated with multiple sclerosis, are not present in significant amounts in MS patients. The research contradicts a previous study and suggests the potential role of oxysterols in MS needs reconsideration.